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The regulation of mitochondrial quality has emerged as a central issue in neurodegeneration, diabetes, and cancer. We utilized
repeated low-dose applications of the complex I inhibitor 1-methyl-4-phenylpyridinium (MPP
þ) over 2 weeks to study cellular
responses to chronic mitochondrial stress. Chronic MPP
þ triggered depletion of functional mitochondria resulting in
diminished capacities for aerobic respiration. Inhibiting autophagy/mitophagy only partially restored mitochondrial content.
In contrast, inhibiting activation of extracellular signal-regulated protein kinases conferred complete cytoprotection with
full restoration of mitochondrial functional and morphological parameters, enhancing spare respiratory capacity in MPP
þ
co-treated cells above that of control cells. Reversal of mitochondrial injury occurred when U0126 was added 1 week after
MPP
þ, implicating enhanced repair mechanisms. Chronic MPP
þ caused a 490% decrease in complex I subunits, along with
decreases in complex III and IV subunits. Decreases in respiratory complex subunits were reversed by co-treatment with U0126,
ERK1/2 RNAi or transfection of dominant-negative MEK1, but only partially restored by degradation inhibitors. Chronic MPP
þ
also suppressed the de novo synthesis of mitochondrial DNA-encoded proteins, accompanied by decreased expression of the
mitochondrial transcription factor TFAM. U0126 completely reversed each of these deﬁcits in mitochondrial translation and
protein expression. These data indicate a key, limiting role for mitochondrial biogenesis in determining the outcome of injuries
associated with elevated mitophagy.
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Mitochondrial dysfunction has long been implicated in
Parkinson’s disease (PD) pathogenesis.
1 Reduced mitochon-
drial complex I activity is observed in the substantia nigra of
patients with PD. Neurotoxins, such as rotenone or 1-methyl-
4-phenylpyridinium (MPP
þ), which inhibit complex I of the
mitochondrial respiratory chain, cause degeneration of
dopaminergic neurons. Recently, diverse proteins involved
in familial PD, including a-synuclein, Parkin, DJ-1, and PTEN-
induced kinase 1, have been implicated in regulating
mitochondrial dynamics and quality control.
1
Akeyelementinmitochondrialqualitycontrolinvolvesauto-
phagic targeting of mitochondria for lysosomal degradation.
Recent studies implicate induction of the autophagy-lysosome
pathway in genetic and toxin models of PD.
2–5 Decreases in
chaperone-mediated autophagy,
6 elicit further increases in
macroautophagy (hereafter autophagy), but this compensa-
tory increase may ultimately prove detrimental.
7 Although
autophagosomes are observed in substantia nigra neurons of
PD and Lewy body dementia patients,
8,9 whether autophagy
is protective or detrimental may depend on interactions of this
pathway with other metabolic or reparative pathways.
We previously demonstrated that acute MPP
þ or 6-hydro-
xydopamine (6-OHDA) treatments induce autophagy and
mitochondrial degradation in SH-SY5Y cells, mediated by
activation of extracellular signal-regulated protein kinases
(ERK).
2,4 Given that chronic or repetitive micro-insults have
been proposed as possible contributing factors for human
neurodegenerative diseases,
10 and chronic PD models may
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Lewy body-like structures,
11,12 we modiﬁed our MPP
þ injury
model to cause gradual cell death over a 2-week period
to study the potential roles of compensatory or repair
pathways.
Retinoic acid-differentiated SH-SY5Y cells were treated
withmultiplelow dosesofMPP
þ,resulting instrikingchanges
in mitochondrial morphology, function and autophagy, with
depletionofnuclearDNA-encodedmitochondrial proteinsand
impaired translation of mitochondrial DNA (mtDNA)-encoded
proteins. Similar to the acute model, inhibition of autophagy
using siRNA to the essential autophagy proteins Atg7 or
microtubule-associatedprotein 1light chain3 (LC3)conferred
partial protection against autophagic cell death. In contrast to
the acute model, however, the MPP
þ-induced disruption in
mitochondrial morphology, protein expression, and function
was completely reversed by inhibition of ERK1/2 activation.
These data suggest that in the chronic setting, blunting the
rapid mitochondrial turnover induced by MPP
þ serves to
prevent autophagic cell death, while allowing compensatory/
reparative biogenesis responses to develop.
Results
Characterization of a 2-week model of progressive
MPP
þ toxicity. Retinoic acid-differentiated SH-SY5Y cells
were treated with lower doses of MPP
þ (in fresh medium)
three times a week, resulting in time- and dose-related
neuronal cell death over 2 weeks (Supplementary Figure
S1A). Chronic MPP
þ treatment caused fragmentation of the
reticular mitochondrial network observed in control cells, with
isolated, sometimes enlarged, mitochondria (Figure 4b),
reductions in mitochondrial membrane potential (Supplemen-
tary Figure S1B), and numerous ultrastructural alterations
(Figure 4d). The mitochondrial matrix was pale with
disorganized cristae often restricted to the periphery.
Quantitative ultrastructural analysis revealed signiﬁcant
increases in the percentage of both the smallest
(r0.2mm
2) and largest (43.0mm
2) mitochondrial proﬁles,
with increased circularity of those 41mm
2 of area, consistent
with swelling (Supplementary Figures S1C–E).
Chronic MPP
þ increased autophagic ﬂux in SH-SY5Y
cells. GFP-LC3 is an established marker of pre-autophago-
somal membranes (phagophores) and early autophagic
vacuoles (AVs). In stable GFP-LC3-expressing, neuronal-
differentiated SH-SY5Y cells, chronic MPP
þ treatment led to
a reduction in very ﬁne GFP-LC3 granules and an increase in
coarse GFP-LC3 puncta, often with ring-like morphology
(Figures 1a–c). Ultrastructural analysis conﬁrmed increased
AVs in the cell body and in neurites (Figures 1d–f). Chronic
MPP
þ treatment also signiﬁcantly increased the average
Figure 1 Selective mitophagy is induced in the 2-week MPP
þ model. MPP
þtreatment (250mM) 2 weeks induced formation of enlarged, coarse GFP-LC3 puncta,
some displaying ring-like or bead-like morphology (b, arrows), compared with control (a). Autophagic puncta were also identiﬁed by immunostaining for endogenous LC3
(b,inset)(scalebar¼20mm).Thereweresigniﬁcanttime-anddose-relatedincreasesincoarseGFP-LC3puncta(c).**Po0.01MPP
þ versusCtrl.
wPo0.01500mMversus
250mM. Electron microscopy revealed increased autolysosomal structures in neurites after MPP
þ treatment (e) compared with control neurites (d) (scale bar¼1mm),
quantiﬁed as increases in either the number of AVs in neurites or the number of neurites containing AVs (f)* * Po0.01, MPP
þ versus control, t-test, and chi-square test,
respectively). RepresentativeLC3western blot shows increasedLC3 II elicitedby MPP
þ in thepresenceof baﬁlomycin,addedduring theﬁnal 24h to prevent degradationof
newly formed AVs (g), and ﬂux analysis using the change in LC3 II/actin ratios in the presence versus absence of baﬁlomycin conﬁrmed a signiﬁcant increase, particularly at
the lower dose (h, n¼3). **Po0.01, *Po0.05, MPP
þversus Ctrl. Western blot showed mitochondrial protein loss (PDH, P110), with no change in endoplasmic reticulum
proteins cytochrome p450 reductase (CPR) or calnexin (i)
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Cell Death and Diseasesize of monodansylcadavarine ﬂuorescent puncta (Supple-
mentary Figures S2A and B), consistent with fusion and
maturation to autolysosomes.
Treatment with baﬁlomycin A1, an inhibitor of early AV
acidiﬁcation and fusion to lysosomes, was used to arrest
degradation of LC3 II, the form of LC3 that is covalently bound
to autophagic membranes. The difference in LC3 II levels in
the presence and absence of baﬁlomycin reﬂects the
degradative ﬂux of autophagosomes in that time frame.
13 In
contrast to acute MPP
þ toxicity, chronic MPP
þ caused a
slight decrease in the steady-state LC3 II level. As reported in
other cell types, induction of autophagy can cause a decrease
in LC3 II levels due to increased turnover of LC3 protein.
13
The addition of baﬁlomycin A1 to MPP
þ-treated cells caused
agreaterincreaseinLC3IIlevelsthanthatobservedincontrol
cells, indicating an increase in LC3 turnover in cells treated
chronically with MPP
þ, particularly at the lower dose (Figures
1g and h). There was mitochondrial protein loss, but no
marked change in two endoplasmic reticulum proteins
(Figure 1i), indicating induction of selective mitophagy.
Autophagy does not have a major, determining role for
cell fate during chronic MPP
þ toxicity. In the acute
MPP
þ model, inhibition of autophagy does not prevent
mitochondrial damage, but reduces autophagic cell death.
4
In the chronic model, RNAi of Atg7 or LC3 attenuated the
increase in LC3 II and reduced the number of autophagic
vacuoles (Figures 2a and b), but resulted in only modest
protection (Supplementary Figure S2C). Interestingly, Atg7
knockdown protected MPP
þ-treated cells against mitochon-
drial swelling (Figure 2b), inhibited the loss of mitochondrial
protein p60 and PDH (Figure 2c; Supplementary Figure S2D)
and conferred partial improvement in maximal oxygen
consumption rates (OCR) (Figure 2d), which were not
observed in the acute model.
4 These data suggest that
limiting the autophagic response may unmask other com-
pensatory responses in the chronic MPP
þ model.
Inhibition of ERK1/2 activation reversed structural
damage to mitochondria and preserved levels of mito-
chondrial complex proteins in chronic MPP
þ-treated
cells. ERK1/2 has been implicated in the regulation of
autophagy and mitophagy,
2,4,14 showing a time-related
40–50% increase, peaking and then decreasing after each
MPP
þ pulse (Figures 3a and b). Increased ERK1/2 activity
was observed using an in vitro kinase pull-down assay
(Figure 3c) and a luciferase assay detecting the in situ
activity of transfected ERK2 or its kinase-dead control
(Figure 3d).
Inhibiting the upstream MAPK/ERK1/2 kinase (MEK) by
adding U0126 with each dose of MPP
þ conferred nearly
complete protection against MPP
þ-induced cell death
(Figure 4a). This protection was not due to decreased
expression of dopamine transporter, increased expres-
sion of vesicular monoamine transporter, or interference
with the acute effects of MPP
þ on mitochondrial respi-
ration (Supplementary Figures S3A and B). Instead,
U0126 reversed the mitochondrial morphology changes
(Figure 4b) and the loss of mitochondrial proteins
(Figure 4c; Figure 5c) observed in cells chronically
stressed with MPP
þ. U0126/MPP
þ co-treated cells dis-
played relatively uniform mitochondria with intact inner
and outer membranes and preserved cristae (Figure 4d).
The degree of protection was much greater than that
observed by inhibiting autophagy alone, implicating other
mechanisms to promote the integrity of chronically injured
mitochondria.
MPP
þ can directly inhibit complex I (NADH-ubiquinone
oxidoreductase) activity of the mitochondrial electron trans-
port chain although other mechanisms of toxicity have also
been implicated.
15 MPP
þ caused 490% decrease in the
nuclear-encoded alpha subunit 9 (NDUFA9), with complete
reversal by U0126 (Figures 5a and b). Similar results
were observed for the complex I subunit NDUFB8 and for
proteins in complex IV (Figure 5c), with a lesser effect on
complex III and no effect on complex V-alpha. The decreased
respiratory protein expression could be partially attributed
to the combined activities of the proteasome, autophagy-
lysosome system and the mitochondrial LON peptidase 1
(Supplementary Figures S3C–F). As the U0126 data impli-
cated the MEK/ERK signaling pathway, we transfected
SH-SY5Y cells with either siRNA targeting ERK1/2
(Figure 5g; Supplementary Figure S3G) or dominant-negative
MEK1 (DN-MEK1; Supplementary Figures S4A and B).
Figure 2 Inhibiting autophagy conferred partial protection in the 2-week
MPP
þ model. Either Atg7 or Atg8 (LC3B) siRNA reduced the LC3 II increase
elicited by MPP
þ (250mM 10 days with 10nM baﬁlomycin for the last 4h) (a).
Electron microscopy conﬁrmed reduced AVs (arrows) in Atg7 siRNA and MPP
þ
co-treated cells (b, 250mM 10 days) compared with MPP
þ-treated cells.
Improvementof mitochondrialmorphologywas also observed(b, star). Atg7protein
knockdown ameliorated MPP
þ-induced reductions of mitochondrial protein p60
and PDH (c; see Supplementary Figure S2D for densitometry), with a modest
recovery in FCCP-elicited maximal OCR in Atg7 siRNA knockdown cells compared
with control siRNA-treated cells (**Po0.01 versus si-ctrl) (d)
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Cell Death and DiseaseEither of these methods also attenuated the MPP
þ-elicited
decrease in mitochondrial respiratory complex proteins.
Amelioration of MPP
þ induced structural changes is
associated with restoration of basal function and
enhanced spare respiratory capacity. Analysis of live cell
aerobic respiration revealed that U0126 not only reversed the
MPP
þ-induced decrease in basal respiration (the mean of the
ﬁrst four time points in Figure 5d), but also caused a further
increase in FCCP-induced maximal mitochondrial respiration
(Figures 5d and e). If cells were cultured in galactose for 24h
prior to analysis to induce dependence on mitochondrial
respiration,
16 MPP
þ reduced cellular ATP concentrations, and
this effect was also rescued by U0126 (Figure 5f). Moreover,
the spare respiratory capacity
17 or mitochondrial reserve
capacity (RC), deﬁned as the difference between maximal
FCCP-induced respiration and basal respiration, was increased
above the baseline control cell level by approximately six-fold in
MPP
þ-injured cells rescued by U0126 (Figure 5e).
To distinguish prevention of injury from enhanced compen-
sation or recovery, we conducted experiments in which the
MEK1/2 inhibitor was added 1 week after beginning MPP
þ
Figure 3 Chronic MPP
þ treatment increased ERK1/2 activity. A time-related increase of ERK1/2 phosphorylation was observed by 16h after each pulse of 250mM
MPP
þ (a and b). ERK1/2 immunoprecipitated from control and MPP
þ-treated cells were analyzed for activity in phosphorylating myelin basic protein (MBP) (c). Intracellular
ERK activation was measured using the Elk1 trans-Reporting System (d) in cells transfected with wild-type (WT) or kinase-deﬁcient (KD) ERK2. **Po0.01, ERK2-WT
(MPP
þ versus Ctrl)
Figure 4 Inhibiting ERK1/2 activation protects against cell death and restores mitochondrial morphology. The MEK inhibitor U0126 restored the viability of cells treated
with MPP
þ (a); preventedMPP
þ-induced mitochondrial fragmentation, formation of giant mitochondria, and disruption of mitochondrial interconnectivity (b, 250mM MPP
þ,
2 weeks; immunostain for mitochondrial protein p60; scale bar¼20mm); and reduced chronic MPP
þ-induced mitochondrial protein P110 loss (c). Compared with control
mitochondria, 250mM MPP
þ  2 weeks caused loss, disarray, and disruption of mitochondrial cristae (d). Many mitochondrial proﬁles are small and fragmentated (chevron)
but some become giant or swollen (arrow), showing evagination (star). Co-treatment with MPP
þ and U0126 reversed these changes (d, scale bar: 500nm). **Po0.01,
U0126
þ versus Veh
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Cell Death and Diseasetreatments (Supplementary Figures S4C–F). At 1 week, there
are already signiﬁcant alterations in mitochondrial structure
and function. Addition of U0126 during the second week of
continued MPP
þ treatments signiﬁcantly restored mitochon-
drial structure and function (Supplementary Figure S4F),
implicating the involvement of reparative pathways.
Inhibiting MEK/ERK activation restores indices of mito-
chondrial biogenesis in MPP
þ-treated cells. Peroxisome
proliferator-activated receptor gamma coactivator 1-alpha
(PGC-1a), nuclear respiratory factor 1 (NRF-1), and mito-
chondrial transcription factor A (TFAM) regulate mito-
chondrial biogenesis. Whereas the former two factors act
as co-regulators of nuclear transcription, PGC-1a also
functions in the mitochondria,
18 and TFAM has an impor-
tant role in mtDNA stability and the biosynthesis of the
13 mtDNA-encoded respiratory chain subunits.
There were no signiﬁcant changes in the levels of PGC-1a
or NRF-1 (Figure 6a; Supplementary Figures S5A and B),
although subcellular localization of PGC-1a was altered.
In control cells, PGC-1a was colocalized with mitochondrial
marker p60, as described in other systems.
18 Signiﬁcant
nuclear signal was not observed, consistent with its constitu-
tive nuclear export unless phosphorylated.
19 MPP
þ elicited
dissociation of cytoplasmic PGC-1a granules from mitochon-
dria (Figures 6b and c; Supplementary Figure S5C), which
was opposed by U0126. There were no signiﬁcant changes
in PGC-1a mRNA levels (Supplementary Figure S5D).
Figure 5 Inhibiting ERK1/2 activation restores respiratory complex protein expression and function. A signiﬁcant decrease of NDUFA9 protein was observed in cells with
250mM MPP
þ  2weeks, which was prevented by 5mM U0126 (a, b, n¼4). **Po0.01, MPP
þ versus ctrl, ctrlþU0126, and MPP
þ/U0126. The complex I subunit
NDUFB8, complex IV-cytochrome oxidase subunit II and complex III core 2 were also decreased with MPP
þ, and restored by co-treatment with U0126 (c). Mitochondrial
oxygenconsumptionwasanalyzedusinganXF24ExtraceullarFluxAnalyzer.Oxygenconsumptionrate(OCR)curvesareshownunderbasalconditions(d)andafteraddition
of 1mM oligomycin (D-1), 300nM FCCP (D-2), 120mM 2-DG (D-3), and 1mM rotenone (D-4). MPP
þ caused signiﬁcant decrease of basal (before 1) and maximal (between
2 and 3) FCCP-induced OCR. U0126 not only reversed the MPP
þ-induced OCR inhibition, but also increased mitochondrial reserve capacity (RC) beyond that of control
cells (e). **Po0.01 MPP
þ versus Ctrl, ctrl þU0126, and MPP
þ þU0126;
wPo0.01 MPP
þ þU0126 versus ctrl or ctrlþU0126. Cells were shifted into galactose as a
fuel source for 24h to stimulate dependence on mitochondrial respiration. Under this condition, MPP
þ elicited a reduction in ATP levels that was reversed by concurrent
treatmentwithU0126.*Po0.05asindicated(f).RNAi-mediatedknockdownofERK1/2alsodiminishedthedecreaseinTFAM,complexIandIVsubunitsthatwereelicitedby
MPP
þ (250mM, 2 weeks) (g; Supplementary Figure S3G for densitometry)
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Cell Death and DiseaseIn contrast, TFAM protein was signiﬁcantly decreased after
chronic MPP
þ treatment (Figures 6d and e). TFAM mRNA
levels were not signiﬁcantly decreased (Supplementary
Figure S5D), whereas inhibition of the mitochondrial
Lon peptidase 1 produced restoration of TFAM levels in
MPP
þ-treated cells (Supplementary Figure S3F), implicating
a degradative process. As mitochondrially localized PGC-1a
binds the D-loop region of mtDNA, where it interacts with
TFAM,
18 and TFAM is central to transcription of mitochondrial
genes, we directly studied mitochondrial protein synthesis by
[
35S]-methionine pulse labeling. Whereas a single dose of
250mM MPP
þ had little effect on mitochondrial translation,
chronic administration of MPP
þ over 1 week signiﬁcantly
inhibited biosynthesis of the 13 mtDNA-encoded respiratory
chain subunits (Figures 7a and c). However, it has no
apparent effect on nuclear DNA-encoded protein translation
(Figure7b). TheMEKinhibitor U0126 preventedthe decrease
in TFAM protein levels in MPP
þ-treated cells (Figures 6d
and e), and restored translation of the mtDNA-encoded
proteins (Figures 7a and c). ERK1/2 siRNA protected TFAM
levels in MPP
þ-treated cells (Figure 5g; Supplementary
Figure S3G). Furthermore, overexpression of TFAM-HA
reversed MPP
þ-induced decreases in respiratory complex
I, III, and IV subunits (Figure 6f, Supplementary Figure S5E).
Discussion
Low dose, repeated MPP
þ administration caused signiﬁcant
loss of functional mitochondria, accompanied by increased
mitophagy, alterations in nuclear-encoded biogenesis pro-
teins and suppression of mitochondrial translation. While
suppressing autophagy conferred only partial restoration of
mitochondrial content, the MEK inhibitor U0126 conferred
complete restoration of mitochondrial protein content,
morphology, and function. Similar protective effects were
observed after use of ERK1/2 siRNA or DN-MEK1 to
downregulate the ERK1/2 signaling pathway. These changes
were accompanied by recovery of TFAM levels and restored
translationofmtDNA-encoded respiratorysubunits,indicating
thatsuppressionofmitochondrialbiogenesishasanimportant
role in the loss of mitochondrial function accompanying
chronic, low-dose exposures to MPP
þ.
Mitochondrial respiration is tightly linked to ATP production.
Neurons and differentiated neuronal cells are largely depen-
dent upon oxidative phosphorylation and usually exhibit a
substantialmitochondrialRC(alsoknownassparerespiratory
capacity), to rapidly meet the requirements of increased
functional demand and stress.
17 Indeed, the RC is a major
determinant of the outcome of neuronal excitotoxicity,
Figure6 EffectsofchronicMPP
þ onmitochondrialbiogenesisproteins.MPP
þ treatment(250mM,2weeks)didnotsigniﬁcantlychangethetotalPGC-1aandNRF-1
protein levels (a); however, MPP
þ caused a loss of PGC-1a granules from mitochondria by double immunostaining (b, scale bar: 20mm; Supplementary Figure S5C).
Relocation of PGC-1a from mitochondria to cytosol was further studied by western blot of mitochondrial and cytosolic fractions prepared using the FOCUS SubCell kit
(G-Biosciences, St Louis, MO, USA) (c). TFAM was signiﬁcantly decreased after MPP
þ treatment, prevented by U0126 (d and e). **Po0.01 MPP
þ versus Ctrl,
CtrlþU0126, and MPP
þ þ U0126, n¼4 for (e). Overexpression of TFAM restored the expression levels of complex I (NDUFA9), III core2, and IV-II subunits in
MPP
þ-injured cells (f; Supplementary Figure S5E for densitometry)
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Cell Death and Diseaseischemia, and oxidative stress.
17,20 Our data indicate that
chronic MPP
þ exposure not only inhibited basal mitochon-
drial respiration, but also diminished the RC. Notably, injury
combined with inhibition of ERK1/2 activation resulted in a
greater RC than observed basally in uninjured cells, suggest-
ing a biogenesis-related adaptation.
Althougha singlelow dose ofMPP
þ was sufﬁcienttoinhibit
oxygen consumption (Supplementary Figure S3B), presum-
ably through direct inhibition of complex I activity, it was
insufﬁcient to cause either mitochondrial translation deﬁcits
or cell death. With repeated, chronic exposures, a signiﬁcant
decrease in the expression of mitochondrial respiratory
complex proteins, particularly complex I, IV, and III subunits,
contributed to a more permanent loss of respiratory function.
Thesedata indicate thatadditional cell biological mechanisms
maybemoreimportanttoMPP
þ toxicitythansimplyitsdirect,
immediate effect on complex I activity. In addition to
autophagy and biogenesis, as observed in this study,
microtubule-dependent trafﬁcking could also impact func-
tionallevelsofmitochondriainneurons,andseveralcomplexI
inhibitors have been shown to impair microtubule function.
15
Blocking different protease degradation pathways partially
prevented the MPP
þ-induced decreases in mitochondrial
respiratory complex proteins, suggesting that degradation is
only one of the mechanisms leading to decreased expression
levels. Indeed, after 1 week of MPP
þ treatment, there was
substantial inhibition of mtDNA-, but not nuclear DNA-,
encoded protein synthesis. It is possible that decreases in
expression of mtDNA-encoded proteins can impair the overall
stability of mitochondrial complexes, resulting in enhanced
degradation of nuclear DNA-encoded subunits. Although we
didn’t observe notable changes in nuclear DNA-encoded
protein synthesis, nor were there signiﬁcant changes in the
mRNA levels of several nuclear-encoded subunits, the
possibility of post-transcriptional or translational regulation
of these proteins remains.
Increasing evidence indicates that ERK1/2 signaling has a
central role in regulating mitochondrial function.
21,22 ERK1/2
activation leads to the loss of mitochondrial membrane
potential and mitochondrial swelling in renal proximal tubular
cells,
23 promotes ROS production and mitochondrial calcium
elevations in ischemia,
24 and increases Bax protein expres-
sion and release of cytochrome c.
25 The degree of mitophagy
elicited by ERK activation is directly correlated with its
mitochondrial localization.
2 As with acute exposures to
MPP
þ or 6-OHDA,
2,4 ERK1/2 was activated, albeit to a
lower level, in the chronic MPP
þ model.
It is known that the effects of ERK signaling in mediating
multiple cellular functions are related not only to the
magnitude of activation, but also to subcellular compartmen-
talization and temporal patterns of activation.
26 In the chronic
MPP
þ model,MPP
þ wasadministratedthreetimesperweek
Figure 7 MPP
þ inhibits synthesis of mtDNA-encoded respiratory subunits, restored by U0126. A representative autoradiogram showed that MPP
þ treatment for
1 week caused marked decreases in newly synthesized
35S-Met-labeled mtDNA-encoded translation products, reversed by co-treatment with U0126 (a). In contrast,
overall protein translation levels assessed in the absence of emetine revealed no obvious effects on total (predominantly nuclear-encoded) protein synthesis (b).
The graph (c) is a quantiﬁcation of three independent pulse-labeling experiments normalized by Coomassie Brilliant Blue stain. **Po0.01 MPP
þ versus Ctrl, CtrlþUO,
MPP
þ þUO.
wPo0.05 CtrlþUO or MPP
þ þUO versus Ctrl
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Cell Death and Diseasefor 2 weeks and caused multiple cycles of periodic activation.
This pattern of ERK activation might be associated with
distinct effects on regulating mitochondrial turnover versus
biogenesis between acute and chronic MPP
þ models, and
explain why multiple administrations of MPTP are typically
needed to elicit parkinsonian injury in mice. At this point, it is
unknown whether the effects of ERK on mitochondrial
biogenesis is mediated through cytoplasmic, nuclear or
mitochondrial signaling, as ERK is known to trafﬁc to each
of these compartments with different temporal patterns of
activation.
In addition to its previously described role in promoting
mitophagy,
2 the current study reveals a novel role for ERK1/2
in modulating mitochondrial protein synthesis (Figure 7). Both
effects would synergize in reducing levels of functional
mitochondria. Studies in other cell types implicate ERK1/2 in
promoting glycolytic metabolism to provide intermediates
compatible with rapid growth,
27 while decreasing mitochon-
drial function.
22 Although decreases in mitochondrial biogen-
esis may confer growth advantages for transformed cells, the
loss of mitochondrial content likely contributes to the toxic
effects of MPP
þ in neuronal cells. Notably, protection
afforded by U0126, which inhibited mitophagy as well as
reversing the biogenesis deﬁcit, was much more complete
than inhibiting degradation alone. Moreover, even when
ERK1/2 inhibition was delayed to the second week of MPP
þ
treatments following development of signiﬁcant mitochondrial
injury, there was restoration of mitochondrial structure and
function, indicating a key role for reparative mitochondrial
biogenesis in determining successful adaptation to chronic
intoxication.
Mitochondrial biogenesis is regulated by PGC-1a, NRF-1,
and TFAM.
28 TFAM is responsible for initiating synthesis of
mtDNA-encoded respiratory chain proteins. TFAM knockout
mice exhibit respiratory chain deﬁcits and reduced mtDNA in
midbrain DA neurons,
29 whereas overexpression of TFAM
elicits an increase in mtDNA and mitochondrial respiratory
chain proteins.
30 We found that low dose, repetitive expo-
sures to MPP
þ signiﬁcantly decreased TFAM protein
expression, reversed by co-treatment with U0126- or ERK1/
2-targeted siRNA. Although siRNA knockdown of the mito-
chondrial LON peptidase 1 partially restored TFAM and
mitochondrial respiratory protein levels, the more complete
reversal observed with U0126 implicate additional mechan-
isms, potentially related to protein synthesis. Depending on
the cellular context, ERK1/2 may either destabilize
31 or
stabilize
32 mRNA species. Thus, the effects of ERK1/2
inhibition on biogenesis may depend upon whether basal or
injury-stimulated contexts are studied. U0126 shows no basal
effects on TFAM or mitochondrial respiratory protein levels,
whereas showing striking effects in reversing the MPP
þ-
induced changes in protein translation and degradation. The
ability of overexpressed TFAM to reverse the MPP
þ-induced
decreases in mitochondrial respiratory complex proteins
conﬁrmed the importance of TFAM modulation in chronic
MPP
þ toxicity.
Although the total level of PGC-1a was not affected by
chronic MPP
þ, a decreased mitochondrial localization of
PGC-1 a was observed. PGC-1a is not only located in the
nucleus, but also in the mitochondria where it interacts with
TFAM to regulate mitochondrial biogenesis.
18 Thus, altered
localization of PGC-1a may cooperate with the loss of TFAM
expression to impair mitochondrial biogenesis. Inhibiting
ERK1/2 activation also restored mitochondrial distribution of
PGC-1a. Although there were no changes in NRF-1 expres-
sion observed in our chronic MPP
þ setting, the possibility
of functional alterations due to altered phosphorylation
remains.
33
MPP
þ sensitivity in cells is correlated with DAT expression
and inversely correlated with expression of vesicular mono-
aminetransporter2(VMAT2).
34,35Repeatedadministrationof
U0126 caused an increase in DAT and a decrease in VMAT2,
indicating that the protection elicited by U0126 was not due to
alteredtransportofMPP
þ.Moreover,U0126didnotaffectthe
kinetics of acute respiratory responses to MPP
þ, and
conferred protection even when administered only during
the second week of toxicity. Therefore, the major protective
effect of U0126 in the chronic MPP
þ model is likely to involve
restoration of mitochondrial protein synthesis in conjunction
with partial reduction of mitochondrial degradation.
The autophagy-lysosomal degradation pathway is recog-
nizedasakeyadaptiveresponse inthepathogenesisofmany
neurodegenerative diseases including PD.
36 In acute injury,
autophagy-lysosomal dysfunction has been demonstrated,
but the role of autophagy may be inﬂuenced by additional
compensatory mechanisms in a chronic low-dose toxicity
setting. Although the current data demonstrate that ERK1/2-
dependent autophagic cell death is also implicated in chronic
MPP
þ toxicity, there are several signiﬁcant differences
between acute and chronic systems. In the acute model,
inhibiting MEK-ERK1/2 signaling prevents autophagy/mito-
phagy and reduces cell death, but has no signiﬁcant effect on
mitochondrial morphology
4 or mitochondrial translation
(Supplementary Figure S6). In the chronic model, the MEK
inhibitor not only inhibited cell death but also resulted in
restorationofmitochondrialstructure andfunction, evenwhen
applied 1 week after initiation of MPP
þ injury. This difference
may be attributed to the greater capacity for repair in less
severely, but chronically injured cells. In the acute model, a
large percentage of mitochondria are damaged, which may
exceed the ability of the cell to successfully repair/regenerate
sufﬁcient functional mitochondria. However, in the chronic
MPP
þ model, the turnover of damaged mitochondria,
particularly when slowed by inhibiting ERK1/2, may occur at
a rate more compatible with mitochondrial biogenesis.
It is interesting that inhibition of autophagy by Atg7 siRNA
also seemed to alleviate some of the mitochondrial morpho-
logical and functional abnormalities caused by MPP
þ. Taken
together with the U0126 data, these results suggest that
blunting the robust mitochondrial degradation response
induced by MPP
þ, which is associated with autophagic cell
death in several neuronal injury models,
2,4,37 allows for
eventual structural and functional mitochondrial recovery in
the context of chronic low-dose injury.
In summary, we discovered a key role for mitochondrial
biogenesis in adaptation to chronic parkinsonian neuronal
injury elicited by repeated administration of MPP
þ in
RA-differentiated SH-SY5Y cells. These data not only
strengthen a growing body of data implicating dysregulation
of the autophagy-lysosome system in PD pathogenesis but
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in determining the outcome of autophagy induction. The ERK1/2
signaling pathway has a central role in the regulation of
chronic MPP
þ toxicity, with effects on mitochondrial content,
quality, and function. Although autophagy and mitochondrial
dysfunction are implicated in both acute and chronic MPP
þ
neurotoxin models, there were striking differences in the
reversibility of mitochondrial structural and functional para-
meters. These data indicate that the chronic MPP
þ model
may be particularly useful for studying mechanisms that
regulate localized repair and restoration of mitochondrial
function in response to damaging Parkinsonian stresses.
Materials and Methods
Cell lines and treatment. SH-SY5Y cells (ATCC, Manassas, VA, USA),
maintained in antibiotic-free Advanced Dulbecco’s modiﬁed Eagle’s medium with
5% heat-inactivated fetal calf serum (BioWhittaker, Walkersville, MD, USA), 2mM
glutamine and 10mM HEPES, were used at passages 30–45. Cells were plated at
3 10
4/cm
2 in 6-, 24-, 48-well plates or LabTek II coverglass chamber slides
(Nalge Nunc International/Thermo Fisher, Pittsburgh, PA, USA) and treated with
10mM retinoic acid (RA) to induce neuronal differentiation for 72h prior to and
during each experiment. RA inhibits proliferation
38 and these differentiated
SH-SY5Y cells can be maintained for weeks. Cells were treated with 250 or
500mM MPP
þ three times per week for up to 2 weeks. Some cultures also
received baﬁlomycin-A (5nM; Calbiochem, San Diego, CA, USA), 1,4-diamino-
2,3-dicyano-1,4-bis[2-aminophenylthio] butadiene (U0126) (5mM; Promega,
Madison, WI, USA) or E64D (10mM, Calbiochem). A GFP-LC3-expressing stable
SH-SY5Y cell line was used to assess MPP
þ-induced LC3 puncta formation.
2
Cell viability was measured using Alamar Blue (Trek Diagnostics, Cleveland,
OH, USA), excitation 540nm, emission 590nm, in a Spectromax M2 microplate
reader (Molecular Devices, Sunnyvale, CA, USA).
RNA interference. Cells were transfected with small interfering RNA (siRNA)
targeting human Atg7, the human Atg8 homolog LC3B,
4 human ERK1 (50-CAG
CUGAGCAAUGACCAUA-30) and ERK2 (50-GACACAACACCUCAGCAAU-30)
(Sigma, St. Louis, MO, USA) or a control non-targeting siRNA pool (Dharmacon,
Lafayette, CO, USA) at 2 days before and 3 days after the ﬁrst dose of MPP
þ.
Efﬁcacy and speciﬁcity of knockdown was assessed by western blot, conﬁrming
that siRNA-mediated knockdown of protein expression persisted for more than
10 days after the second dose of siRNA.
39
DNA transfection. Differentiated SH-SY5Y cells transfected with pCMV6-
Neo vector containing HA-tagged human TFAM, which was constructed from
TFAM-tGFP plasmid (Origene, Rockville, MD, USA) by replacing the tGFP-tag
sequence with an HA-tag coding sequence (50-TACCCATACGATGTTCCAGA
TTACGCTTAA-30), were treated with chronic MPP
þ 48h after transfection. In
some experiments, differentiated SH-SY5Y stably expressing dominant-negative
MEK1 (DN-MEK1, S217A) cloned to pBABEpuro eukaryotic expression vector
(gift from Dr. CJ Marshall, Cancer Research UK, London, England) were used.
Transmission electron microscopy. Cells were ﬁxed in 2.5% glutar-
aldehyde at 41C, processed, and photographed using a JEM 1210 transmission
electron microscope (JEOL, Peabody, MA, USA) as previously reported,
4 using
NIH ImageJ software to analyze mitochondrial proﬁles.
Fluorescence microscopy. SH-SY5Y cells ﬁxed with 3% paraformalde-
hyde or methanol were probed with mouse anti-LC3 (1:100, Clone 2G6,
Nanotools, San Diego, CA, USA) or mouse anti-human mitochondrial antigen
60KD (clone 113–1; 1:100; BioGenex, San Ramon, CA, USA), followed by Cy3-
conjugated anti-rabbit antibody (1:500; Jackson Immuno-Research Laboratories,
West Grove, PA, USA) or Alexa Fluor 488-conjugated antibody (1:500; Molecular
Probes, Eugene, OR, USA), and imaged at 541/572nm and 490/520nm
(excitation/emission), respectively.
Mitochondrial membrane potential measurement. Cells were
labeled with 5,50,6,60-tetrachloro-1,10,3,30-tetraethyl benzimidazolyl carbocyanine
iodide (JC-1, 5mg/ml; Molecular Probes) for 15min at 371C and rinsed with PBS.
The signal intensity was measured by ﬂuorescence well scan photometry
(red, ex 535/ em 590nm; green, ex 485/ em 530nm) in a Spectromax M2
microplate reader (Molecular Devices), or imaged using an Olympus ﬂuorescence
microscope IX-71 (Olympus America Inc., Melville, NY, USA).
Western blot analysis and densitometry. Cells were disrupted in 0.1%
Triton X-100 with protease/phosphatase inhibitors, electrophoresed through 5–15%
gradient polyacrylamide gels and immunoblotted as described previously,
4 using
mouse anti-phospho-ERK1/2 (1:1000, Cell Signaling, Beverly, MA, USA), rabbit
anti-ERK1/2 (1:10000, Millipore, Billerica, MA, USA), mouse anti-p110 mitochon-
drial protein (1:500; Oncogen, Boston, MA, USA), mouse anti-human mitochondrial
antigen 60KD rabbit anti-human tom20 (1:10000, Santa Cruz Biotechnology, Santa
Cruz, CA, USA), mouse anti-pyruvate dehydrogenase E2 subunit (1:2000;
Molecular Probes), mouse anti-LC3 (1:500, clone 5F10, Nanotools), rabbit
anti-calnexin (1:4000, Calbiochem), rabbit anti-cytochrome p450 reductase
(CPR, 1:4000, Santa Cruz), rabbit anti-ATG7 (1:1000, Rockland, Gilbertsville,
PA, USA), Rabbit anti-HA (1:1000, Rockland), mouse anti-nuclear-encoded NADH-
ubiquinone oxidoreductase alpha subunit 9 (NDUFA9, 1:1000, Abcam, Cambridge,
MA, USA), MitoProﬁle Total OXPHOS antibody cocktail (1:1000, MitoSciences,
Eugene, Oregon, USA), rabbit anti-mitochondrial transcription factor A (TFAM,
1:10000, provided by Dr. C Cameron), rabbit anti-nuclear respiratory factor 1
(NRF-1, 1:5000, Abcam), rabbit anti-peroxisome proliferator-activated receptor
gamma coactivator 1-alpha (PGC1a, 1:500, Santa Cruz), mouse anti-b-actin
(1:10000, Sigma), and rabbit anti-glyceraldehyde-3-phosphate dehydrogenase
(GAPDH, 1:10000, Abcam). Densitometry was performed using the electrophoresis
documentation and analysis system 120 (Kodak, Rochester, NY, USA).
ERK1/2 activity assay. In situ ERK1/2 activity was assessed using the
PathDetect Elk1 trans-Reporting System (Stratagene, La Jolla, CA, USA) as
previous reported.
2 This system measures ERK1/2-dependent transactivation of
Elk1 in cells, which drives expression of luciferase. Endogenous ERK1/2 was
isolated from treated cells using the MAPK Immunoprecipitation Kinase Assay Kit
(Upstate Biotechnology, NY, USA) for in vitro activity assay using myelin basic
protein as substrate.
Mitochondrial respiration assay. Oxygen consumption rates (OCR) in
living cells were analyzed at baseline and following the sequential addition of 1mM
oligomycin, 300nM FCCP, 120mM 2-deoxyglucose and 1mM rotenone (ﬁnal
concentrations) using the XF24 Extracellular Flux Analyzer (Seahorse Bioscience,
North Billerica, MA, USA). Steady-state cellular ATP concentrations were
measured using the ATPLite-M luminescence assay (PerkinElmer; Waltham,
MA, USA) and a Synergy 2 Multi-Mode Microplate Reader (BioTek, Winooski,
VT, USA) in a black 96-well microplate in glucose-free DMEM with galactose;
under these conditions cells rely on OXPHOS for ATP generation.
16
[
35S]-Methonine labeling of mitochondrial translation products
in vivo. Mitochondrial protein synthesis was assayed by [
35S]-methionine pulse
labeling experiments.
40 Cells were washed and incubated in methionine-free and
cysteine-free DMEM for 30min, and then incubated for 5min at 371C in the same
medium containing 100mg/ml of the eukaryotic translation inhibitor emetine. After
the addition of 0.2mCi (1175Ci/mmol) [
35S]-methionine, the cells were incubated
for 2h. Lysates (25mg protein) were resolved on SDS-PAGE gels, and quantiﬁed
by phosphorimaging.
Statistics. All graphed data represent mean þ/  S.E.M. from replicate
experiments. Data were analyzed by one-way analysis of variance with post-hoc
Fisher’s least signiﬁcant difference, two-way ANOVA or chi-square test as
appropriate. Values of Po0.05 were considered signiﬁcant.
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